
## Yutaka Kawakami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9496657/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Challenges and experiences to develop a Japanese language course for international medical students in Japan: Maximising acquisition of Japanese language by applying adult learning theories. Asia Pacific Scholar, 2022, 7, 3-8.	0.2	0
2	TPT1 Supports Proliferation of Neural Stem/Progenitor Cells and Brain Tumor Initiating Cells Regulated by Macrophage Migration Inhibitory Factor (MIF). Neurochemical Research, 2022, 47, 2741-2756.	1.6	3
3	Positive Effects of Oral Antibiotic Administration in Murine Chronic Graft-Versus-Host Disease. International Journal of Molecular Sciences, 2021, 22, 3745.	1.8	8
4	Adoptive cell therapy using tumorâ€infiltrating lymphocytes for melanoma refractory to immuneâ€checkpoint inhibitors. Cancer Science, 2021, 112, 3163-3172.	1.7	11
5	Guidelines for clinical evaluation of anti ancer drugs. Cancer Science, 2021, 112, 2563-2577.	1.7	17
6	Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease. International Journal of Molecular Sciences, 2021, 22, 6114.	1.8	20
7	Immune-resistant mechanisms in cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 810-817.	1.0	39
8	Enhanced antiâ€ŧumor effects of the PDâ€1 blockade combined with a highly absorptive form of curcumin targeting STAT3. Cancer Science, 2020, 111, 4326-4335.	1.7	39
9	Senescenceâ€associated secretory phenotype promotes chronic ocular graftâ€vsâ€host disease in mice and humans. FASEB Journal, 2020, 34, 10778-10800.	0.2	26
10	Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecologic Oncology, 2020, 159, 329-334.	0.6	23
11	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
12	Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. BMC Cancer, 2020, 20, 196.	1.1	15
13	NUAK2 localization in normal skin and its expression in a variety of skin tumors with YAP. Journal of Dermatological Science, 2020, 97, 143-151.	1.0	6
14	Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. Oncology Letters, 2020, 21, 1-1.	0.8	10
15	GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. ELife, 2020, 9, .	2.8	41
16	Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget, 2019, 10, 3013-3026.	0.8	13
17	Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for th prognosis of resectable colorectal cancer. British Journal of Cancer, 2019, 121, 659-665.	ne 2.9	84
18	Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter. Gynecologic Oncology, 2019, 155, 340-348.	0.6	11

#	Article	IF	CITATIONS
19	"Smart Eye Camera": An innovative technique to evaluate tear film breakup time in a murine dry eye disease model. PLoS ONE, 2019, 14, e0215130.	1.1	28
20	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy. Journal of Investigative Dermatology, 2019, 139, 1490-1496.	0.3	15
21	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nature Communications, 2019, 10, 5758.	5.8	29
22	Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome. Medicine (United States), 2019, 98, e16390.	0.4	5
23	Ocular Surface and Tear Film Characteristics in a Sclerodermatous Chronic Graft-Versus-Host Disease Mouse Model. Cornea, 2018, 37, 486-494.	0.9	11
24	Functional Role of Lacrimal Gland Fibroblasts in a Mouse Model of Chronic Graft-Versus-Host Disease. Cornea, 2018, 37, 102-108.	0.9	13
25	Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Cellular and Molecular Immunology, 2018, 15, 953-962.	4.8	47
26	Involvement of local reninâ€angiotensin system in immunosuppression of tumor microenvironment. Cancer Science, 2018, 109, 54-64.	1.7	60
27	Novel elucidation and treatment of pancreatic chronic graft-versus-host disease in mice. Royal Society Open Science, 2018, 5, 181067.	1.1	1
28	Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice. PLoS ONE, 2018, 13, e0203742.	1.1	11
29	Pilot study of WT1 peptide‑pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncology Letters, 2018, 16, 1348-1356.	0.8	9
30	Inhibition of Vascular Adhesion Proteinâ€1 for Treatment of Graftâ€Versusâ€Host Disease in Mice. FASEB Journal, 2018, 32, 4085-4095.	0.2	10
31	Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. Frontiers in Immunology, 2018, 9, 152.	2.2	50
32	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Annals of Gastroenterological Surgery, 2018, 2, 289-303.	1.2	35
33	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	6.3	1,487
34	Immunobiology of theÂMelanoma Microenvironment. , 2018, , 133-142.		0
35	Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid. Scientific Reports, 2017, 7, 41939.	1.6	25
36	Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma. Melanoma Research, 2017, 27, 326-334.	0.6	21

Υυτακά Καωάκαμι

#	Article	IF	CITATIONS
37	Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. European Journal of Cancer, 2017, 86, 15-27.	1.3	61
38	miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncology Letters, 2017, 14, 1355-1362.	0.8	22
39	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 36.	3.5	24
40	Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer. Japanese Journal of Clinical Immunology, 2017, 40, 54-59.	0.0	12
41	Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Japanese Journal of Clinical Immunology, 2017, 40, 68-77.	0.0	22
42	Reduced Expression of VAMP8 in Lacrimal Gland Affected by Chronic Graft-versus-Host Disease. Journal of Ophthalmology, 2017, 2017, 1-10.	0.6	6
43	MIF: functions in brain and glioblastoma. Oncotarget, 2017, 8, 46706-46707.	0.8	4
44	CHD7 promotes proliferation of neural stem cells mediated by MIF. Molecular Brain, 2016, 9, 96.	1.3	28
45	Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity. European Journal of Cancer, 2016, 62, 54-61.	1.3	10
46	Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. International Immunology, 2016, 28, 393-399.	1.8	50
47	MIF Maintains the Tumorigenic Capacity of Brain Tumor–Initiating Cells by Directly Inhibiting p53. Cancer Research, 2016, 76, 2813-2823.	0.4	54
48	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. , 2016, , 349-358.		0
49	Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. Journal of Investigative Dermatology, 2016, 136, 255-263.	0.3	160
50	Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies. PLoS ONE, 2016, 11, e0146371.	1.1	6
51	MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. ELife, 2016, 5, e09394.	2.8	26
52	Synergistic antiproliferative effect of imatinib and adriamycin in plateletâ€derived growth factor receptorâ€expressing osteosarcoma cells. Cancer Science, 2015, 106, 875-882.	1.7	18
53	Development of Personalized Combination Cancer Immunotherapy Based on the Patients' Immune Status. , 2015, , 255-266.		2
54	Phase I pilot study of Wilms tumor gene 1 peptideâ€pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Science, 2015, 106, 397-406.	1.7	65

#	Article	IF	CITATIONS
55	<i>NUAK2</i> Amplification Coupled with <i>PTEN</i> Deficiency Promotes Melanoma Development via CDK Activation. Cancer Research, 2015, 75, 2708-2715.	0.4	19
56	Aberrant Myosin 1b Expression Promotes Cell Migration and Lymph Node Metastasis of HNSCC. Molecular Cancer Research, 2015, 13, 721-731.	1.5	53
57	Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 287-301.	0.1	0
58	Functional analysis of a novel glioma antigen, EFTUD1. Neuro-Oncology, 2014, 16, 1618-1629.	0.6	10
59	TGF-Î <sup>2</sup> 1 in Tumor Microenvironments Induces Immunosuppression in the Tumors and Sentinel Lymph Nodes and Promotes Tumor Progression. Journal of Immunotherapy, 2014, 37, 63-72.	1.2	35
60	Induction of Immunoregulatory CD271+ Cells by Metastatic Tumor Cells That Express Human Endogenous Retrovirus H. Cancer Research, 2014, 74, 1361-1370.	0.4	44
61	Towards the introduction of the â€~Immunoscore' in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	2.1	1,151
62	A phase Ιl study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). Journal of Translational Medicine, 2014, 12, 108.	1.8	75
63	NOD- <i>Rag2<sup>null</sup> IL-2Rγ<sup>null</sup></i> Mice: An Alternative to NOG Mice for Generation of Humanized Mice. Experimental Animals, 2014, 63, 321-330.	0.7	16
64	Intratumoral Injection of BCG-CWS-Pretreated Dendritic Cells Following Tumor Cryoablation. Methods in Molecular Biology, 2014, 1139, 145-153.	0.4	3
65	Prognostic Significance of Interleukin-8 and CD163-Positive Cell-Infiltration in Tumor Tissues in Patients with Oral Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e110378.	1.1	57
66	Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis <i>via</i> CCR4/CCL22 in head and neck squamous cell carcinoma. International Journal of Cancer, 2013, 132, 2755-2766.	2.3	70
67	Cancerâ€induced immunosuppressive cascades and their reversal by molecularâ€ŧargeted therapy. Annals of the New York Academy of Sciences, 2013, 1284, 80-86.	1.8	18
68	Targeting FSTL1 Prevents Tumor Bone Metastasis and Consequent Immune Dysfunction. Cancer Research, 2013, 73, 6185-6193.	0.4	72
69	Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer, 2013, 16, 100-110.	2.7	54
70	Immunochemoradiotherapy for Patients with Oral Squamous Cell Carcinoma: Augmentation of OK-432-Induced Helper T Cell 1 Response by 5-FU and X-ray Irradiation. Neoplasia, 2013, 15, 805-814.	2.3	18
71	Prognostic Impact of Expression of Bcl-2 and Bax Genes in Circulating Immune Cells Derived from Patients with Head and Neck Carcinoma. Neoplasia, 2013, 15, 305-IN35.	2.3	16
72	Generation of Human Melanocytes from Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2013, 989, 193-215.	0.4	20

#	Article	IF	CITATIONS
73	CCL2 is critical for immunosuppression to promote cancer metastasis. Clinical and Experimental Metastasis, 2013, 30, 393-405.	1.7	120
74	Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy. Frontiers in Oncology, 2013, 3, 136.	1.3	22
75	Expression and localization of aging markers in lacrimal gland of chronic graft-versus-host disease. Scientific Reports, 2013, 3, 2455.	1.6	23
76	Sox6 Up-Regulation by Macrophage Migration Inhibitory Factor Promotes Survival and Maintenance of Mouse Neural Stem/Progenitor Cells. PLoS ONE, 2013, 8, e74315.	1.1	21
77	Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clinical and Developmental Immunology, 2013, 2013, 1-13.	3.3	132
78	Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments. , 2013, , 307-323.		2
79	Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease. PLoS ONE, 2013, 8, e64724.	1.1	50
80	Presence and Physiologic Function of the Renin–Angiotensin System in Mouse Lacrimal Gland. , 2012, 53, 5416.		19
81	Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma. Molecular Cancer Research, 2012, 10, 454-468.	1.5	32
82	Transplantation of side population cells restores the function of damaged exocrine glands through clusterin. Stem Cells, 2012, 30, 1925-1937.	1.4	39
83	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
84	Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. Journal of Cell Science, 2012, 125, 3210-20.	1.2	82
85	Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. Oral Oncology, 2012, 48, 678-685.	0.8	11
86	Accumulation of Secretory Vesicles in the Lacrimal Gland Epithelia Is Related to Non-Sjögren's Type Dry Eye in Visual Display Terminal Users. PLoS ONE, 2012, 7, e43688.	1.1	26
87	Donor mesenchymal stem cells trigger chronic graft-versus-host disease following minor antigen-mismatched bone marrow transplantation. Nature Precedings, 2012, , .	0.1	0
88	Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells. Journal of Immunology, 2012, 189, 2110-2117.	0.4	136
89	Cancerâ€ŧestis antigen <scp>BORIS</scp> is a novel prognostic marker for patients with esophageal cancer. Cancer Science, 2012, 103, 1617-1624.	1.7	30
90	Downregulation of KIF23 suppresses glioma proliferation. Journal of Neuro-Oncology, 2012, 106, 519-529.	1.4	82

Υυτακά Καωάκαμι

#	Article	IF	CITATIONS
91	Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. Development (Cambridge), 2012, 139, e1908-e1908.	1.2	1
92	Human Tumor Antigens Recognized by T Cells and Their Implications for Cancer Immunotherapy. , 2012, , 335-345.		0
93	Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Molecular Cancer, 2011, 10, 60.	7.9	69
94	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	1.8	139
95	Generation of Human Melanocytes from Induced Pluripotent Stem Cells. PLoS ONE, 2011, 6, e16182.	1.1	102
96	The mechanisms of cancer immunoescape and development of overcoming strategies. International Journal of Hematology, 2011, 93, 294-300.	0.7	106
97	Adjuvant effects of formalinâ€inactivated HSV through activation of dendritic cells and inactivation of myeloidâ€derived suppressor cells in cancer immunotherapy. International Journal of Cancer, 2011, 128, 119-131.	2.3	10
98	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	3.2	108
99	AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6597-6602.	3.3	46
100	Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors. Journal of Immunology, 2011, 187, 27-36.	0.4	87
101	Identification of HLAâ€A2―and A24â€restricted Tâ€cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. International Journal of Cancer, 2010, 126, 919-929.	2.3	39
102	Targeted inhibition of ILâ€10â€secreting CD25 <sup>â^'</sup> Treg <i>via</i> p38 MAPK suppression in cancer immunotherapy. European Journal of Immunology, 2010, 40, 1011-1021.	1.6	33
103	Aberrant Fatty Acid-Binding Protein-7 Gene Expression in Cutaneous Malignant Melanoma. Journal of Investigative Dermatology, 2010, 130, 221-229.	0.3	30
104	Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. Journal of Translational Medicine, 2010, 8, 84.	1.8	23
105	Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Letters, 2010, 291, 150-157.	3.2	55
106	The RNA Silencing Technology Applied by Lentiviral Vectors in Oncology. Methods in Molecular Biology, 2010, 614, 187-199.	0.4	10
107	Involvement of Hyaluronan and Its Receptor CD44 with Choroidal Neovascularization. , 2009, 50, 4410.		28
108	Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells. Clinical Cancer Research, 2009, 15, 5733-5743.	3.2	31

Υυτακά Καωάκαμι

#	Article	IF	CITATIONS
109	Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cell, 2009, 15, 195-206.	7.7	735
110	RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis and Rheumatism, 2009, 60, 2193-2200.	6.7	511
111	Simultaneous suppression of MITF and BRAF <sup>V600E</sup> enhanced inhibition of melanoma cell proliferation. Cancer Science, 2009, 100, 1863-1869.	1.7	31
112	Activation of dendritic-like cells and neural stem/progenitor cells in injured spinal cord by GM-CSF. Neuroscience Research, 2009, 64, 96-103.	1.0	39
113	Epithelial Mesenchymal Transition in Human Ocular Chronic Graft-Versus-Host Disease. American Journal of Pathology, 2009, 175, 2372-2381.	1.9	61
114	Functional recovery after spinal cord injury in mice through activation of microglia and dendritic cells after ILâ€12 administration. Journal of Neuroscience Research, 2008, 86, 1972-1980.	1.3	44
115	Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. International Journal of Cancer, 2008, 122, 2274-2279.	2.3	18
116	Identification of a WT1 proteinâ€derived peptide, WT1 <sub>187</sub> , as a HLAâ€A*0206â€restricted, WT1â€specific CTL epitope. Microbiology and Immunology, 2008, 52, 551-558.	0.7	17
117	Isolation and characterization of dendritic cells from common marmosets for preclinical cell therapy studies. Immunology, 2008, 123, 566-574.	2.0	13
118	Novel System Evaluating In Vivo Pathogenicity of Desmoglein 3-Reactive T Cell Clones Using Murine Pemphigus Vulgaris. Journal of Immunology, 2008, 181, 1526-1535.	0.4	69
119	Autoreactive T-cell responses to myeloperoxidase in patients with antineutrophil cytoplasmic antibody-associated vasculitis and in healthy individuals. Modern Rheumatology, 2008, 18, 593-600.	0.9	11
120	A Pilot Study of Human Interferon  Gene Therapy for Patients with Advanced Melanoma by in vivo Transduction Using Cationic Liposomes. Japanese Journal of Clinical Oncology, 2008, 38, 849-856.	0.6	21
121	Helicobacter pylori eradication shifts monocyte FcÎ <sup>3</sup> receptor balance toward inhibitory FcÎ <sup>3</sup> RIIB in immune thrombocytopenic purpura patients. Journal of Clinical Investigation, 2008, 118, 2939-49.	3.9	114
122	Suppression of Alkali Burn-Induced Corneal Neovascularization by Dendritic Cell Vaccination Targeting VEGF Receptor 2. , 2008, 49, 2172.		19
123	Autoreactive T-cell responses to myeloperoxidase in patients with antineutrophil cytoplasmic antibody-associated vasculitis and in healthy individuals. Modern Rheumatology, 2008, 18, 593-600.	0.9	11
124	Inflammation and pathogenic fibrosis in human ocular chronic graft versus host disease. Inflammation and Regeneration, 2008, 28, 529-536.	1.5	1
125	Dendritic cell based personalized immunotherapy based on cancer antigen research. Frontiers in Bioscience - Landmark, 2008, 13, 1952.	3.0	15
126	Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis. Clinical Cancer Research, 2007, 13, 6267-6274.	3.2	12

#	Article	IF	CITATIONS
127	Role of Heat Shock Protein 47, a Collagen-Binding Chaperone, in Lacrimal Gland Pathology in Patients with cGVHD. , 2007, 48, 1079.		36
128	Lentiviral vector-mediated RNAi and its use for cancer research. Future Oncology, 2007, 3, 655-664.	1.1	30
129	Identification of a neuron-specific human gene, KIAA1110, that is a guanine nucleotide exchange factor for ARF1. Biochemical and Biophysical Research Communications, 2007, 364, 737-742.	1.0	11
130	Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2. , 2007, 48, 4795.		14
131	Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflammatory Bowel Diseases, 2007, 13, 865-873.	0.9	23
132	Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. International Journal of Cancer, 2007, 120, 1704-1711.	2.3	48
133	T Helper Type 2-Biased Natural Killer Cell Phenotype in Patients with Pemphigus Vulgaris. Journal of Investigative Dermatology, 2007, 127, 324-330.	0.3	36
134	Dendritic Cells Transduced with Autoantigen FCRLA Induce Cytotoxic Lymphocytes and Vaccinate against Murine B-Cell Lymphoma. Journal of Investigative Dermatology, 2007, 127, 2818-2822.	0.3	12
135	Evaluation of platelet kinetics in patients with liver cirrhosis: Similarity to idiopathic thrombocytopenic purpura. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 112-118.	1.4	56
136	The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. Journal of Experimental Medicine, 2006, 203, 1651-1656.	4.2	614
137	Neurogenic potential of progenitors derived from human circulating CD14 + monocytes. Immunology and Cell Biology, 2006, 84, 209-217.	1.0	45
138	Possible involvement of allogeneic antigens recognised by donor-derived CD4+ cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. British Journal of Haematology, 2006, 132, 56-65.	1.2	13
139	Endothelial Differentiation Potential of Human Monocyte-Derived Multipotential Cells. Stem Cells, 2006, 24, 2733-2743.	1.4	116
140	Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis and Rheumatism, 2006, 54, 1946-1951.	6.7	90
141	Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. International Journal of Cancer, 2006, 118, 472-476.	2.3	58
142	Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. International Journal of Cancer, 2006, 118, 942-949.	2.3	25
143	A Novel Cancer Testis Antigen That Is Frequently Expressed in Pancreatic, Lung, and Endometrial Cancers. Clinical Cancer Research, 2006, 12, 191-197.	3.2	38
144	Enhancement of Immunologic Tumor Regression by Intratumoral Administration of Dendritic Cells in Combination with Cryoablative Tumor Pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation. Clinical Cancer Research, 2006, 12, 7465-7475.	3.2	91

#	Article	IF	CITATIONS
145	A New Melanoma Antigen Fatty Acid–Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy. Cancer Research, 2006, 66, 4443-4449.	0.4	51
146	Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica, 2006, 91, 1436-7.	1.7	43
147	Systematic Identification of Human Melanoma Antigens Using Serial Analysis of Gene Expression (SACE). Journal of Immunotherapy, 2005, 28, 10-19.	1.2	34
148	Binding of β2–glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood, 2005, 105, 1552-1557.	0.6	92
149	Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. British Journal of Haematology, 2005, 131, 472-479.	1.2	41
150	Novel autoantibodies to a voltage-gated potassium channel KV1.4 in a severe form of myasthenia gravis. Journal of Neuroimmunology, 2005, 170, 141-149.	1.1	75
151	Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients. International Journal of Cancer, 2005, 114, 283-290.	2.3	24
152	Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. International Journal of Cancer, 2005, 116, 925-933.	2.3	28
153	Immunological detection of altered signaling molecules involved in melanoma development. Cancer and Metastasis Reviews, 2005, 24, 357-366.	2.7	10
154	Donor Fibroblast Chimerism in the Pathogenic Fibrotic Lesion of Human Chronic Graft-Versus-Host Disease. , 2005, 46, 4519.		49
155	Cardiomyogenic Potential of Mesenchymal Progenitors Derived from Human Circulating CD14+ Monocytes. Stem Cells and Development, 2005, 14, 676-686.	1.1	49
156	Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability–Positive Endometrial Cancer. Clinical Cancer Research, 2005, 11, 3949-3957.	3.2	40
157	Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genetics and Cytogenetics, 2005, 157, 1-11.	1.0	46
158	Splenic Macrophages Maintain the Anti-Platelet Autoimmune Response Via Uptake of Opsonized Platelets in Patients with Chronic ITP Blood, 2005, 106, 221-221.	0.6	2
159	Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Science, 2004, 95, 784-791.	1.7	67
160	Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 2004, 124, 796-801.	1.2	51
161	Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene, 2004, 23, 1420-1427.	2.6	71
162	Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene, 2004, 23, 6031-6039.	2.6	177

#	Article	IF	CITATIONS
163	Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning. Oncogene, 2004, 23, 7772-7779.	2.6	28
164	Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene, 2004, 23, 8796-8804.	2.6	91
165	Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathology, 2004, 21, 35-38.	1.1	35
166	Immunohistochemical analysis of SOX6 expression in human brain tumors. Brain Tumor Pathology, 2004, 21, 117-120.	1.1	14
167	Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis and Rheumatism, 2004, 50, 3658-3662.	6.7	64
168	Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer. International Journal of Cancer, 2004, 108, 712-724.	2.3	15
169	Implantation of dendritic cells in injured adult spinal cord results in activation of endogenous neural stem/progenitor cells leading to de novo neurogenesis and functional recovery. Journal of Neuroscience Research, 2004, 76, 453-465.	1.3	72
170	Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. Journal of Gene Medicine, 2004, 6, 715-723.	1.4	161
171	Defective vasculogenesis in systemic sclerosis. Lancet, The, 2004, 364, 603-610.	6.3	261
172	Development of Immunotherapy for Pancreatic Cancer. Pancreas, 2004, 28, 320-325.	0.5	13
173	Augmentation of Antitumor Immune Responses by Multiple Intratumoral Inoculations of Replication-Conditional HSV and Interleukin-12. Journal of Immunotherapy, 2004, 27, 92-98.	1.2	14
174	Impaired Platelet Production and Autoantibody-Mediated Platelet Destruction Are Two Major Causes for Prolonged Thrombocytopenia after Allogeneic HSCT Blood, 2004, 104, 2256-2256.	0.6	0
175	Multi-Lineage Potential of Human Monocyte-Derived Mesenchymal Progenitors (MOMPs) Blood, 2004, 104, 3595-3595.	0.6	Ο
176	A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology, 2003, 37, 1267-1276.	3.6	95
177	Identification of Human Tumor Antigens Recognized by T-Cells and Their Use for Immunotherapy. International Journal of Hematology, 2003, 77, 427-434.	0.7	3
178	Autoreactive T cells to the P3A+ isoform of AChR α subunit in myasthenia gravis. Journal of Neuroimmunology, 2003, 137, 177-186.	1.1	6
179	Human circulating CD14+monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. Journal of Leukocyte Biology, 2003, 74, 833-845.	1.5	275
180	Preferentially Expressed Antigen of Melanoma (PRAME) in the Development of Diagnostic and Therapeutic Methods for Hematological Malignancies. Leukemia and Lymphoma, 2003, 44, 439-444.	0.6	43

#	Article	IF	CITATIONS
181	A Novel Protein Highly Expressed in Testis Is Overexpressed in Systemic Sclerosis Fibroblasts and Targeted by Autoantibodies. Journal of Immunology, 2003, 171, 6883-6890.	0.4	14
182	Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Research, 2003, 13, 521-530.	0.6	69
183	Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood, 2003, 101, 621-623.	0.6	44
184	Periductal Area as the Primary Site for T-Cell Activation in Lacrimal Gland Chronic Graft-Versus-Host Disease. , 2003, 44, 1888.		111
185	Human melanoma antigens recognized by CD8+ T cells. , 2003, , 47-74.		1
186	Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Research, 2003, 63, 5564-72.	0.4	94
187	Spleen Is a Primary Site for Activation of Platelet-Reactive T and B Cells in Patients with Immune Thrombocytopenic Purpura. Journal of Immunology, 2002, 168, 3675-3682.	0.4	139
188	A simple and reliable behavioral analysis of locomotor function after spinal cord injury in mice. Journal of Neurosurgery: Spine, 2002, 97, 142-147.	0.9	38
189	Restricted T-cell receptor β-chain usage by T cells autoreactive to β2–glycoprotein I in patients with antiphospholipid syndrome. Blood, 2002, 99, 2499-2504.	0.6	33
190	Rapid and efficient generation of lentivirally gene-modified dendritic cells from DC progenitors with bone marrow stromal cells. Journal of Immunological Methods, 2002, 271, 153-165.	0.6	17
191	Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: Relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis and Rheumatism, 2002, 46, 2148-2159.	6.7	74
192	Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: Application to enzyme-linked immunosorbent assay. Arthritis and Rheumatism, 2002, 46, 2742-2747.	6.7	44
193	In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Therapy, 2002, 9, 142-148.	2.2	47
194	Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Therapy, 2002, 9, 356-364.	2.2	44
195	Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. Journal of Dermatological Science, 2001, 25, 36-44.	1.0	14
196	Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood, 2001, 98, 130-139.	0.6	117
197	Autoreactive CD4+ T-cell clones to $\hat{l}^22$ -glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood, 2001, 98, 1889-1896.	0.6	71
198	Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. British Journal of Haematology, 2001, 112, 916-926.	1.2	74

#	Article	IF	CITATIONS
199	Increase of oligodendrocyte progenitor cells after spinal cord injury. Journal of Neuroscience Research, 2001, 65, 500-507.	1.3	70
200	Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia, 2001, 34, 1-7.	2.5	155
201	Induction of antigen-specific human CD4+ T cell anergy by peripheral blood DC2 precursors. European Journal of Immunology, 2001, 31, 2547-2557.	1.6	134
202	Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes. Journal of Immunology, 2001, 166, 2871-2877.	0.4	65
203	Autoantibodies to the Amino-Terminal Fragment of β-Fodrin Expressed in Glandular Epithelial Cells in Patients with Sjol`gren's Syndrome. Journal of Immunology, 2001, 167, 5449-5456.	0.4	34
204	T cells that are autoreactive to $\hat{I}^2$ -glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis and Rheumatism, 2000, 43, 65-75.	6.7	70
205	Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis and Rheumatism, 2000, 43, 1074.	6.7	125
206	T Cell Immune Responses Against Melanoma and Melanocytes in Cancer and Autoimmunity. Pigment Cell & Melanoma Research, 2000, 13, 163-169.	4.0	44
207	Recognition of Shared Melanoma Antigens in Association With Major HLA-A Alleles by Tumor Infiltrating T Lymphocytes From 123 Patients With Melanoma. Journal of Immunotherapy, 2000, 23, 17-27.	1.2	125
208	New Cancer Therapy by Immunomanipulation. Cornea, 2000, 19, S2-S6.	0.9	18
209	Immunotherapy of Melanoma Using T-Cell-Defined Antigens. , 2000, , 77-92.		0
210	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 1998, 4, 321-327.	15.2	1,693
211	The Use of Melanosomal Proteins in the Immunotherapy of Melanoma. Journal of Immunotherapy, 1998, 21, 237-246.	1.2	91
212	Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma. Microbiology and Immunology, 1998, 42, 803-813.	0.7	5
213	Differential Expression of MART-1 in Primary and Metastatic Melanoma Lesions. Journal of Immunotherapy, 1997, 20, 460-465.	1.2	53
214	Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use for Immuno-Gene Therapy. International Reviews of Immunology, 1997, 14, 173-192.	1.5	87
215	Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. Journal of Immunological Methods, 1997, 202, 13-25.	0.6	97
216	Human tumor antigens recognized by T-cells. Immunologic Research, 1997, 16, 313-339.	1.3	119

#	Article	IF	CITATIONS
217	Identification of human melanoma antigens recognized by T cells and their use for immuno-gene therapy The Journal of the Japanese Society of Lymphoreticular Tissue Research, 1997, 37, 137-144.	0.0	0
218	Human Melanoma Antigens Recognized by T Lymphocytes Keio Journal of Medicine, 1996, 45, 100-108.	0.5	35
219	Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp IOO in Metastatic Melanoma Cell Lines and in In Situ Lesions. Journal of Immunotherapy, 1996, 19, 192-205.	1.2	130
220	T-cell recognition of self peptides as tumor rejection antigens. Immunologic Research, 1996, 15, 179-190.	1.3	53
221	Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 1996, 184, 2207-2216.	4.2	287
222	Identification of the Genes Encoding Cancer Antigens: Implications for Cancer Immunotherapy. Advances in Cancer Research, 1996, 70, 145-177.	1.9	65
223	Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. International Journal of Cancer, 1995, 62, 97-102.	2.3	115
224	Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. Journal of the National Cancer Institute, 1995, 87, 280-285.	3.0	205
225	T-Cell Receptor Repertoire in Tumor-Infiltrating Lymphocytes. Analysis of Melanoma-Specific Long-Term Lines. Journal of Immunotherapy, 1994, 16, 85-94.	1.2	31
226	Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunology, Immunotherapy, 1994, 39, 73-83.	2.0	0
227	T-Cell Recognition of Human Melanoma Antigens. Journal of Immunotherapy, 1993, 14, 88-93.	1.2	59
228	Expansion of Tumor-Infiltrating Lymphocytes from Human Tumors Using the T-Cell Growth Factors Interleukin-2 and Interleukin-4. Journal of Immunotherapy, 1993, 14, 336-347.	1.2	14
229	Molecular Mechanisms Used by Tumors to Escape Immune Recognition. Journal of Immunotherapy, 1993, 14, 182-190.	1.2	115
230	Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes. Journal of Immunotherapy, 1992, 12, 203-206.	1.2	24
231	Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1991, 32, 465-477.	1.1	85
232	Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Human Immunology, 1990, 28, 198-207.	1.2	22
233	Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. International Journal of Immunopharmacology, 1989, 11, 63-69.	1.1	28
234	Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. International Journal of Immunopharmacology, 1988, 10, 485-488.	1.1	26

#	Article	IF	CITATIONS
235	Chemoimmunotherapy of Spontaneous Mammary Tumors in C3H/OuJ Mice by Cyclophosphamide and Interleukin-2. Annals of the New York Academy of Sciences, 1988, 532, 482-485.	1.8	Ο
236	Suppression by Cannabinoids of a Cloned Cell Line with Natural Killer Cell Activity. Experimental Biology and Medicine, 1988, 187, 355-359.	1.1	24
237	In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. , 0, .		1